Impact of Oncotype DX Test on Quality-Adjusted Life Expectancy and Costs in Patients with Stage II Colon Cancer
In an independent study led by authors Neal Meropol, University Hospital Seidman Cancer Center and Case Western Research University; Gary Lyman, Duke University; and Rebecca Chien and John Hornberger, Cedar Associates, results showed that clinical use of the Oncotype DX Recurrence Score to assess risk of recurrence in T3 stage II colon cancers with intact mismatch repair (MMR-P) is likely to improve quality-adjusted life expectancy and be cost-saving from a societal perspective. Patient age and adverse effects associated with chemotherapy are important considerations in adjuvant treatment decisions. The study, "Use of a multigene prognostic assay for selection of adjuvant chemotherapy in patients with stage II colon cancer: Impact on quality-adjusted life expectancy and costs" (N. J. Meropol et al, Abstract #491), will be presented in a poster on Saturday, January 22.
"Our data support the notion that use of a genomic test like the Recurrence Score Assay may potentially reduce chemotherapy use, improve quality adjusted survival, and save health care costs," said Neal J. Meropol, M.D., Chief of the Division of Hematology and Oncology at University Hospitals Seidman Cancer Center and Case Western Reserve University.
Genomic Health and TGen Publish Laboratory Study Identifying Genes that May Impact Effectiveness of Oxaliplatin
Separately, Genomic Health and the Translational Genomics Research Institute published a laboratory study in Molecular Cancer Research that describes the identification of 27 genes that, when silenced, altered the sensitivity of colon tumor cells to the drug oxaliplatin. Oxaliplatin is widely used in colon cancer; however a significant number of patients experience serious side effects. This discove
|SOURCE Genomic Health, Inc.|
Copyright©2010 PR Newswire.
All rights reserved